Enfermedades alérgicas
Kuna P, Jutel M, Pulka G, et al. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study. Clin Ophthalmol. 2023;17:735-746. Published 2023 Mar 4. doi:10.2147/OPTH.S398168
Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Bilastine 0.6% preservative-free eye drops, a once-daily treatment for allergic conjunctivitis [published online ahead of print, 2023 Feb 21]. J Investig Allergol Clin Immunol. 2023;0. doi:10.18176/jiaci.0894
Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: a dose-finding study [published online ahead of print, 2022 Mar 1]. J Investig Allergol Clin Immunol. 2022;0. doi:10.18176/jiaci.0800
Ochoa D, Román M, Belmonte C, et al. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. Adv Ther. 2021;38(7):4070-4081. doi:10.1007/s12325-021-01801-y
Óseo e inmunomodulación / deficiencia de vitamina D
Pérez-Castrillón JL, Dueñas-Laita A, Brandi ML, et al. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. J Bone Miner Res. 2021;36(10):1967-1978. doi:10.1002/jbmr.4387
Pérez-Castrillón JL, Dueñas-Laita A, Gómez-Alonso C, et al. Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial. J Bone Miner Res. 2023;38(4):471-479. doi:10.1002/jbmr.4776
Pérez-Castrillon JL, Usategui-Martín R, Pludowski P. Treatment of Vitamin D Deficiency with Calcifediol: Efficacy and Safety Profile and Predictability of Efficacy. Nutrients. 2022;14(9):1943. Published 2022 May 5. doi:10.3390/nu14091943
Otras publicaciones
Arnaud L, Benech P, Greetham L, et al. APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF-κB activation. Cell Rep. 2022;40(7):111200. doi:10.1016/j.celrep.2022.111200
